Vertex Pharma gets expanded indication for cystic fibrosis treatment from the EC.
The NICE says it will not recommend these drugs.
The Association of National Advertisers responds to the AMA’s recent call for a ban on direct-to...
Xellia Pharmaceuticals has acquired manufacturing facilities in Bedford, Ohio.
Novartis’ once-daily inhaler tops GSK’s inhaler in reducing COPD.
FDA awards Merck KGaA and Pfizer breakthrough therapy designation for metastatic Merkel cell carcinoma treatment.
BioMarin receives unfavorable FDA panel vote on Duchenne muscular dystrophy drug.
Turing Pharmaceuticals to retain drug list price, while offering discounts to hospitals.
Hesperos scientists awarded international prize for accurate new alternative to animal testing of pharmaceuticals.
Global Gaucher disease treatment market value will reach $1.16 billion by 2024, says GlobalData.
Bioinformatics market to grow at CAGR of 21.2% from 2014 to 2020, according to Grand View Research, Inc.
Brickell Biotech secures exclusive world-wide rights to a novel class of RORγ inhibitors for psoriasis and other autoimmune diseases.
MediSapiens Ltd introduces BioIT solution that brings personalized medicine to treatment of cancer patients at the Helsinki University Central Hospital.
Issuance of first U.S. patent directly covering Synthetic Biologics' novel candidate for irritable bowel syndrome with constipation (IBS-C).
Salient CRGT awarded $15 million prime contract to provide IT services to the FDA Center for Veterinary Medicine.
Roche’s Genentech exercises option for Ophthotech’s muscular degeneration drug.
The changing pharmaceutical industry needs diversity, new thinking, and multi-sector experience, according to discussions at Pharma Integrates 2015.
Global type 1 diabetes mellitus market value will exceed $7 billion by 2021, says GBI Research.